IgDraSol's Acquisition

IgDraSol was acquired by Sorrento Therapeutics on September 10, 2013.

IgDraSol is a private company focused on the development of oncologic agents for the treatment of metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC) and other cancers. IgDraSol's lead …

Articles about IgDraSol's Acquisition: